GNF-5 is an inhibitor of Abl that decreases cytokinesis in vitro and displays anti-diabetic, anti-inflammatory, and anti-asthma activities. In vivo, GNF-5 prevents streptozocin-induced loss of pancreatic β-cells and normalizes blood glucose levels. GNF-5 also inhibits OVA-induced increases in IL-13 and CCL2 levels as well as airway resistance in vivo.
| Cas No. | 778277-15-9 |
|---|---|
| Purity | ≥99% |
| Formula | C20H17F3N4O3 |
| Formula Wt. | 418.38 |
| IUPAC Name | N-(2-Hydroxyethyl)-3-(6-{[4-(trifluoromethoxy)phenyl]amino}-4-pyrimidinyl)benzamide |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | G5322 Info Sheet PDF |
|---|
Karunakaran U, Park SJ, Jun do Y, et al. Non-receptor tyrosine kinase inhibitors enhances β-cell survival by suppressing the PKCδ signal transduction pathway in streptozotocin-induced β-cell apoptosis. Cell Signal. 2015 Jun;27(6):1066-74. PMID: 25683919.
Chen S, Tang DD. c-Abl tyrosine kinase regulates cytokinesis of human airway smooth muscle cells. Am J Respir Cell Mol Biol. 2014 Jun;50(6):1076-83. PMID: 24392933.
Cleary RA, Wang R, Wang T, et al. Role of Abl in airway hyperresponsiveness and airway remodeling. Respir Res. 2013 Oct 11;14:105. PMID: 24112389.
